Document:

MASTER
SERVICES AGREEMENT

 

This
Master Services Agreement (this “Agreement”) is entered into as of the 16 day of April, 2012 by and between Vaccinogen,
having its registered address at 5300 Westview Drive, Suite 406, Fredrick, MD 21703 (“Vaccinogen”), and Oncology
Trials Insights, Inc., having its registered address at 950 S. Cherry St., Suite 1210, Denver, Colorado, U.S.A. (“OTI”).
The above parties are hereinafter referred to each as a “Party” and jointly as the “Parties”.

 

WHEREAS,
OTI specializes in providing protocol development, site selection, site enrollment diagnostics, enrollment management, site and
investigator education, and clinical trial awareness services on behalf of clinical trial sponsors;

 

WHEREAS,
Vaccinogen wishes to retain OTI to provide services of site selection, project management, and trial enrollment for the Phase II
Oncovax trial in colon cancer; and

 

WHEREAS,
OTI and Vaccinogen desire to enter into a Master Services Agreement to set forth the terms and conditions under which Vaccinogen
would engage OTI to perform such services in connection with the Project;

 

NOW,
THEREFORE, in consideration of the foregoing and of the covenants, agreements and conditions contained herein, and other good and
valuable consideration, the adequacy and receipt of which are hereby acknowledged, the Parties hereto agree as follows:

 

1           Performance
of Services

 

1.1           OTI
hereby agrees to perform services for Vaccinogen from time to time under the terms set forth in this Agreement. All services performed
by OTI pursuant to the terms of this Agreement shall be referred to herein as “Services.”

 

1.2           Services
to be performed by OTI shall be mutually agreed upon by the Parties and set forth in one or more Project Work Orders. Each Project
Work Order executed and delivered by the Parties is deemed to be incorporated into, and form part of this Agreement, and the terms
of this Agreement shall be construed accordingly. In the event of any conflict between this Agreement and any provision of a Project
Work Order, the terms of this Agreement shall control, except to the extent the Project Work Order expressly states that the provision
in the Project Work Order takes precedent with respect to the Services provided under such Project Work Order.

 

1.3           Changes
in the Services to be provided under a Project Work Order shall be documented in the form of an executed Change Order. No change
to the Scope of Work and/or Budget in respect of the Services to be provided under any Project Work Order shall be effective unless
set forth in a Change Order executed by both Parties.

 

1.4           The
first Project Work Order to be conducted under this Agreement is attached hereto as Exhibit “A.”

 

    	16 April 2012

    	 

    

 

2            Compensation
for Services Rendered

 

2.1           In
consideration for OTI’s performance of the Services described in this Agreement, Vaccinogen shall pay OTI fees in accordance
with and for which a duly executed Project Work Order exists.

 

2.2           OTI
shall provide to Vaccinogen separate invoices for each Project Work Order. All amounts due under any undisputed invoice shall be
paid within 30 days of receipt by Vaccinogen of the applicable invoice.

 

2.3           Additional
services may be contracted separately at the sole discretion and upon mutual agreement of the Parties.

 

3           Compliance

 

3.1           OTI
shall comply with all applicable laws, regulations and guidance documents, including but not limited to, rules governing United
States federal and state healthcare programs, while performing Services under this Agreement.

 

3.2           Vaccinogen
shall comply with all applicable laws, regulations and guidance documents, including but not limited to, rules governing United
States federal and state healthcare programs, while conducting the Clinical Trial.

 

3.3           While
on Vaccinogen’s premises or while acting on behalf of Vaccinogen on the premises of Vaccinogen’s study sites, OTI shall
comply with Vaccinogen’s policies, provided that Vaccinogen has delivered to OTI with a written copy of any such applicable
policies.

 

3.4           Vaccinogen
shall immediately notify OTI with regard to any safety or regulatory issues resulting from or arising out of the Clinical Trial.

 

4           Use
and Disclosure of Confidential Information

 

4.1           In
this Agreement, “Confidential Information” means any and all information, materials, know-how, intellectual property,
technology, data and ideas, whether written, oral or in other form, which is reasonably considered confidential by the disclosing
Party and which is obtained by a Party, or any directors, officers, employees, agents or advisers (“Representatives”)
of a Party, from the other Party or any Representative of such Party, in respect of the Project and/or any related Project Work
Order, with the exception of any information which (i) at the date of its disclosure is publicly known or at any time after that
date becomes publicly known (other than by breach of this Agreement), or (ii) the receiving Party can evidence was in its possession
at the time of disclosure and was not obtained, directly or indirectly, by or as a result of breach of a confidentiality obligation
under this Section 4.

 

4.2           Any
current Project Work Order or potential Project Work Order which is the subject of consideration, evaluation and discussion between
the Parties and the existence and contents of this Agreement shall be considered Confidential Information.

 

    	16 April 2012

    	 

    

 

4.3           The
Parties agree that the Confidential Information may be used solely for the purpose of performing each Party’s obligations
under this Agreement and not for any other purpose. Except as provided in Section 4.6 below, the Confidential Information will
be held in complete and strict confidence and may only be disclosed to Representatives of the Parties on a strict need-to-know
basis for the performance of such Party’s obligations under the Agreement. No Confidential Information received by a Party
may be copied or reproduced in any way without the prior written consent of the other Party.

 

4.4           The
Parties undertake to ensure that each of its Representatives who receive Confidential Information is made aware of and observes
the obligations under this Agreement. For the avoidance of any doubt, any disclosure or unauthorized use of any Confidential Information
under this Agreement by any of the Representatives of a Party shall constitute a breach by the relevant Party of this Agreement.

 

4.5           Upon
written request by either Party, each Party agrees that it will, as soon as reasonably practicable, return or destroy (at the disclosing
Party’s discretion) all copies of any document in such Party’s or such Party’s Representative’s possession
containing or reflecting Confidential Information, provided however that the Parties may retain one copy of such Confidential
Information for purposes of performing their obligations under this Agreement.

 

4.6           Section
4.3 above does not, however, apply to the extent that any Party is required to make a disclosure of Confidential Information by
law or pursuant to any order of court or other competent authority or tribunal or by any applicable stock exchange regulations
or the regulations of any other recognized market place. In the event that any Party would be required to make any such disclosure,
each Party undertakes to give the other Party reasonable notice prior to any such disclosure in order to make it possible for the
other Party to seek an appropriate protective order or other remedy. Each Party also agrees and undertakes to use its best efforts
to ensure that any Confidential Information disclosed under this Section 4.6, to the extent possible, will be treated confidentially
by any party receiving such Confidential Information.

 

4.7           Neither
Party, nor any of its Representatives, makes any representation or warranty, express or implied, as to the accuracy, reliability
or completeness of any of the Confidential Information, and neither Party, nor any of its Representatives, will have any liability
whatsoever to the other Party resulting from any use of the Confidential Information.

 

4.8           OTI
acknowledges that some or all of the Confidential Information, including the discussions between the Parties hereto, may be inside
information under applicable law and that neither OTI nor any of its Representatives may deal in price-affected securities in relation
to the inside information, encourage another person to deal in price-affected securities or disclose the inside information except
as permitted by law.

 

5            Non-solicitation

 

5.1           The
Parties shall not, during the term of this Agreement and for a period of two years following its termination, either directly or
indirectly recruit, solicit, induce or attempt to induce any current director, officer or employee of the other Party (including
any director, officer or employee of any company within the same group as the other Party) to terminate his or her employment with
such Party or otherwise be employed by it or any other person, firm or company and shall not approach any such employee for such
purpose or authorize or approve the taking of such action by any other person without the prior written consent of the other Party.

 

    	16 April 2012

    	 

    

 

5.2           The
Parties shall not, during the term of this Agreement and for a period of two years following its termination, other than in the
ordinary course of business, either directly or indirectly approach, recruit, solicit, induce or attempt to induce any person or
entity that is a customer, supplier, agent, representative or adviser of the other Party, or that the Parties otherwise know has
some form of business relationship of any kind with the other Party, to cease, restrict or vary in any way its relationship with
the other Party without the prior written consent of the other Party, but in any event not in connection with a current or potential
Project Work Order.

 

6           Contacts

 

6.1           All
communications made by Vaccinogen to OTI in connection with the provision of Services under this Agreement or in connection with
any current or potential Project Work Order shall be directed to Joseph D. Giglio, MBA, President and CEO, jgiglio@oncologytrialsinsights.org,
303-759-5579.

 

6.2           All
communications made by OTI to Vaccinogen in connection with the provision of Services under this Agreement or in connection with
any current or potential Project Work Order shall be directed to Michael G. Hanna, Jr., Ph.D., Chairman & CEO, mghannajr@vaccinogeninc.com.
m) 301 793-7736 or o) 301 668-8400.

 

7           Term
and Termination

 

7.1           This
Master Services Agreement shall be effective as of the date first set forth above (the “Effective Date”) and shall
remain in full force and effect until the later of (i) three (3) years after the Effective Date (the “Term”), or (ii)
the date that all Services under all Project Work Orders executed prior to the expiration of the Term are completed, unless otherwise
terminated by the Parties in accordance with this Section 7.

 

7.2           Either
Party may terminate this Agreement immediately upon written notice to the other Party in the event of a breach by the other Party
of a material provision of this Agreement that remains uncured thirty (30) days following the receipt of notice in writing of such
breach from the non-breaching Party.

 

7.3           Termination
or expiration of this Agreement shall not affect any rights or obligations which have accrued prior thereto or in connection therewith,
or any obligations hereunder which by their terms survive termination or expiration.

 

8           Failure
to Perform; Remedies

 

8.1           If
OTI does not provide Services conforming to the Services set forth in each Project Work Order in all material respects, and such
failure is due to a reason other than a force majeure event (as described below in Section 8.2) or Vaccinogen’s negligence or failure
to act as reasonably required under this Agreement, Vaccinogen shall timely notify OTI in writing of such material non-compliance
and shall allow OTI to correct such material non-compliance or provide an acceptable corrective action plan within thirty (30)
days of such notification.

 

    	16 April 2012

    	 

    

 

8.2           Neither
Party shall be liable or deemed to be in default under this Agreement for any delay due to causes beyond the control of the Party,
including but not limited to, war, civil disorders, acts of God or government action, provided that the affected Party promptly
notifies the other Party of the causes and its effects on the Services to be performed hereunder.

 

9           Deliverables,
Work Product & Intellectual Property

 

9.1           All
methodologies, innovations, discoveries and practices conceived, reduced to practice, made or developed by OTI for protocol development,
site selection, site enrollment diagnostics, enrollment management, site and investigator education, and clinical trial awareness
services in connection with OTI’s performance of the Services not exclusively related to the Services and not containing
Vaccinogen Confidential Information shall be the sole property of OTI. All other reports, communications, materials, information,
innovations and discoveries (whether or not patentable or copyrightable) conceived, reduced to practice, made or developed by OTI
solely or jointly with others in connection with OTI’s performance of the Services shall be promptly disclosed to and be the sole
property of Vaccinogen.

 

9.2           Notwithstanding
the foregoing, Vaccinogen shall not acquire ownership of any materials, information, products, costs, operational techniques, financial
and tax information, projections, research and development plans, inventions, trade secrets and know-how and/or other intellectual
property owned by OTI prior to OTI’s performance of Services under this Agreement or that is licensed by OTI from any third party.

 

10          Presentations,
Publications and Publicity

 

10.1           OTI
shall not present or publish, nor submit for publication, any work resulting from the Services without Vaccinogen’s prior
written approval.

 

11          Representation
and Warranties

 

11.1           Each
Party represents and warrants that the total payment for the Services represents fair market value for the Services and has not
been determined in any manner that takes into account the volume or value of any referrals or business between OTI and Vaccinogen.

 

11.2           OTI
and Vaccinogen represent and warrant that the terms of this Agreement are not inconsistent with any other contractual or legal
obligations that the respective Parties may have.

 

12          Independent
Contractor

 

12.1           OTI’s
status under this Agreement is that of an independent contractor.

 

12.2           OTI
shall not be deemed an employee or joint venture partner of Vaccinogen for any purpose whatsoever.

 

    	16 April 2012

    	 

    

 

12.3         This
Agreement shall not entitle OTI to participate in any benefit plan or program of Vaccinogen.

 

12.4         OTI
is not entitled to worker’s compensation coverage by Vaccinogen, and OTI hereby waives any and all rights OTI may have to
be covered under Vaccinogen’s worker’s compensation policies.

 

13          Indemnification

 

13.1         Vaccinogen
hereby agrees to indemnify OTI and its affiliates, employees, directors, officers and agents and hold them harmless against any
liability, judgment, demand, action, suit, loss, damage, cost and other expense (including but not limited to reasonable attorney’s
fees and court costs) (“Liability”) resulting from any third party claims made or proceedings brought against OTI to
the extent that such Liability arises as a result of the Vaccinogen’s negligence, willful misconduct or breach of the representations
and warranties set forth in this Agreement., or OTI’s performance of the Services; except to the extent that such Liability
results from OTI’s negligence, wilful misconduct or breach of the representations or warranties set forth in this Agreement.

 

13.2         OTI
agrees to indemnify Vaccinogen and its affiliates, employees, directors, officers and agents and hold them harmless against Liability
resulting from any third party claims made or proceedings brought against Vaccinogen to the extent that such Liability arises as
a result of OTI’s negligence, willful misconduct or breach of the representations and warranties set forth in this Agreement.

 

14          Waiver

 

14.1         No
waiver of any term or condition of this Agreement in any instance shall be deemed to be or construed as a further or continuing
waiver of such term or condition or of any other term or condition of this Agreement.

 

15          Notices

 

15.1         All
notices hereunder shallbe in writing and shall be effective upon deposit in the United States mail,certified mail, return
receipt requested with postage paid, or personally delivered by express courier, faxed or transmitted by electronic mail as follows:

 

If to OTI, address to:

 

Oncology Trials Insights, Inc.

Attn: Joseph D. Giglio

President and CEO

950 South Cherry Street

Suite 1210

Denver, CO 80246

303-759-5579 (Phone)

303-759-5892 (Fax)

jgiglio@oncologytrialsinsights.org

 

    	16 April 2012

    	 

    

 

with
a copy (which shall not constitute notice) to:

 

Hogan
Lovells US LLP

Attn:
Asher M. Rubin

Harbor
East

100
International Drive, Suite 2000

Baltimore,
MD 21202

410-659-2777
(Phone)

410-659-2701
(Fax) 

asher.rubin@hoganlovells.com

 

If
to Vaccinogen, address to:

 

Vaccinogen

Attn:
Michael G. Hanna, Jr., Ph.D.

Chairman
& CEO

5300
Westview Drive

Suite
406

Fredrick,
MD 21703

Office
301 668 8400

Mobile
301 793 7736

Fax
301 631 2970 

mghannajr@vaccinogeninc.com

 

    	16 April 2012

    	 

    

 

16          Assignment;
Subcontracting

 

16.1           Neither
Party may assign this Agreement or any interest herein, or delegate any duty hereunder, to any third party without the other Party’s
prior written consent (which is in its sole discretion to grant or withhold).

 

16.2           In
the event that OTI is permitted to subcontract any duty hereunder to a third party, such subcontractor shall execute an agreement
in a form acceptable to Vaccinogen obligating such subcontractor to comply with the terms and conditions hereof, and OTI shall
remain responsible and liable for the acts or omissions of such subcontractor activities as if such activities had been performed
by OTI.

 

17          Miscellaneous

 

17.1         This
Agreement contains the entire understanding of the Parties with respect to the subject matter hereof and supersedes all previous
agreements and undertakings with respect thereto. This Agreement may be modified only by written agreement signed by the Parties.

 

17.2         Each
Party agrees and undertakes to hold the other Party harmless from any damages, loss, costs or liability arising out of or in relation
to any breach of this Agreement by a Party or any Representative of a Party.

 

18          Governing
Law and Jurisdiction

 

18.1         This
Agreement shall be governed by and construed in accordance with the laws of Colorado without regard to its principles of conflicts
of laws.

 

18.2         Any
dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof,
shall be finally settled by arbitration in accordance with the JAMS Streamlined Arbitration Rules and Procedures.

 

18.3         The
place of arbitration shall be Denver, Colorado. The language to be used in the proceedings shall be English.

 

18.4         The
Parties undertake and agree that all arbitral proceedings conducted with reference to this arbitration clause will be kept strictly
confidential. This confidentiality undertaking shall cover all information disclosed in the course of such arbitral proceedings,
as well as any decision or award that is made or declared during the proceedings. Information covered by this confidentiality undertaking
may not, in any form, be disclosed to a third party without the prior written consent by the other Party.

 

    	16 April 2012

    	 

    

 

19          Counterparts;
Electronic Signatures

 

19.1         For
the convenience of the Parties, any number of counterparts of this Agreement may be executed by any one or more Parties hereto,
and each such executed counterpart shall be, and shall be deemed to be, an original, but all of which shall constitute, and shall
be deemed to constitute, in the aggregate but one and the same instrument.

 

19.2         
This Agreement may be circulated for signature through electronic transmission, including, without limitation, facsimile and email,
and all signatures so obtained and transmitted shall be deemed for all purposes under this Agreement to be original signatures
until such time, if ever, as original counterparts are exchanged by the Parties.

 

    	16 April 2012

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

 

	Vaccinogen	 	Oncology Trials Insights, Inc.
	 	 	 
	By: 	/s/
Michael G. Hanna, Jr.	 	By:	/s/ Joseph Giglio
	 	 	 	 	 
	Michael. G. Hanna, Jr., Ph.D. 	 	Name:	Joseph Giglio
	 	 	 	 
	Chairman & CEO	 	Title:	President & CEO

  

    	16 April 2012INVESTMENT AGREEMENT

 

THIS
INVESTMENT AGREEMENT (hereinafter referred to as the “Agreement”), dated as of July 18, 2012 (“Execution
Date”) by and between Vaccinogen, Inc., a Maryland corporation (hereinafter referred to as the “Company”), and
Kodiak Capital Group, LLC, a Delaware limited liability company (hereinafter referred to as the “Investor”).

 

WHEREAS,
the parties desire that, upon the terms and subject to the conditions contained herein, the Investor shall invest up to twenty
five million dollars ($25,000,000) to purchase the Company’s Common Stock, $0.0001 par
value per share (the “Common Stock”); and

 

WHEREAS,
such investments will be made in reliance upon the provisions of Section 4(2) under the Securities Act of 1933, as amended
(the “1933 Act”), Rule 506 of Regulation D, and the rules and regulations promulgated thereunder, and/or upon such
other exemption from the registration requirements of the 1933 Act as may be available with respect to any or all of the investments
in Common Stock to be made hereunder; and

 

WHEREAS,
contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration
Rights Agreement substantially in the form attached hereto (the “Registration Rights Agreement”) pursuant to which
the Company has agreed to provide certain registration rights under the 1933 Act, and the rules and regulations promulgated thereunder,
and applicable state securities laws.

 

NOW
THEREFORE, in consideration of the foregoing recitals, which shall be considered an integral part of this Agreement,
the covenants and agreements set forth hereafter, and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Company and the Investor hereby agree as follows:

 

SECTION 1. DEFINITIONS. 

As used in this Agreement, the following
terms shall have the following meanings specified or indicated below, and such meanings shall be equally applicable to the singular
and plural forms of such defined terms.

 

“1933
Act” shall have the meaning set forth in the preamble of this agreement.

 

“1934
Act” shall mean the Securities Exchange Act of 1934, as it may be amended.

 

“Affiliate”
shall have the meaning specified in Section 5(H), below.

 

    	1

    	 

    

 

“Agreement”
shall mean this Investment Agreement.

 

“By-laws”
shall have the meaning specified in Section 4(C).

 

“Certificate
of Incorporation” shall have the meaning specified in Section 4(C).

 

“Closing”
shall have the meaning specified in Section 2(G).

 

“Closing
Date” shall mean no more than five (5) Trading Days following a Put Notice Date.

 

“Commitment
Shares” shall have the meaning specified in Section 12(M).

 

“Common
Stock” shall have the meaning set forth in the preamble of this Agreement.

 

“Company”
shall mean Vaccinogen, Inc., a Maryland corporation.

 

“Control”
or “Controls” shall have the meaning specified
in Section 5(H).

 

“Document
Preparation Fee” shall have the meaning specified in Section 12(M).

 

“Effective
Date” shall mean the date the SEC declares effective under the 1933 Act the Registration Statement covering
the Securities.

 

“Environmental
Laws” shall have the meaning specified in Section 4(M).

 

“Equity
Line Transaction Documents” shall mean this Agreement and the Registration Rights Agreement.

 

“Execution
Date” shall mean the date indicated in the preamble to this Agreement.

 

“Facility
Amount” shall have the meaning specified in Section 2(A).

 

“Indemnities”
shall have the meaning specified in Section 11.

 

“Indemnified
Liabilities” shall have the meaning specified in Section 11.

 

“Ineffective
Period” shall mean any period of time that the Registration Statement or any Supplemental Registration Statement
(as defined in the Registration Rights Agreement between the parties) becomes ineffective or unavailable for use for the sale
or resale, as applicable, of any or all of the Registrable Securities (as defined in the Registration Rights Agreement) for any
reason (or in the event the prospectus under either of the above is not current and deliverable) during any time period required
under the Registration Rights Agreement.

 

    	2

    	 

    

 

“Investor”
shall have the meaning indicated in the preamble of this Agreement.

 

“Material
Adverse Effect” shall have the meaning specified in Section 4(A).

 

“Material
Amount” or “Material in Amount”
shall mean greater than $10,000.

 

“Maximum
Common Stock Issuance” shall have the meaning specified in Section 2(H).

 

“Open
Market Adjustment Amount” shall have the meaning specified in Section 2(I).

 

“Open
Market Share Purchase” shall have the meaning specified in Section 2(I).

 

“Open
Period” shall mean the period beginning on and including the Trading Day immediately following the Effective
Date and ending on the earlier to occur of (i) the date which
is eighteen months (18) months from the Execution Date; or (ii)
termination of the Agreement in accordance with Section 9, below.

 

“Pricing
Period” shall mean the period beginning on the Put Notice Date and ending on and including the date that
is five (5) Trading Days after such Put Notice Date.

 

“Principal
Market” shall mean the American Stock Exchange, Inc., the National Association of Securities Dealers, Inc.
Over-the-Counter Bulletin Board, the NASDAQ National Market System or the NASDAQ SmallCap Market, whichever is the principal market
on which the Common Stock will be listed pursuant to the Company’s plans to become a fully-reporting publicly-listed Company
on a Principal Market.

 

“Prospectus”
shall mean the prospectus, preliminary prospectus, and supplemental prospectus used in connection with the Registration Statement.

 

“Purchase
Amount” shall mean the total amount being paid by the Investor on a particular Closing Date to purchase the
Securities.

 

“Purchase
Price” shall mean eighty percent (80%) of the lowest daily VWAP during the Pricing Period.

 

“Put”
shall have the meaning set forth in Section 2(B)(1) hereof.  

 

“Put
Amount” shall have the meaning set forth in Section 2(B)(1) hereof.  

 

    	3

    	 

    

 

“Put
Notice” shall mean a written notice sent to the Investor by the Company stating the Put Amount in U.S. dollars
the Company intends to sell to the Investor pursuant to the terms of the Agreement and stating the current number of Shares issued
and outstanding on such date.

 

“Put
Notice Date” shall mean the Trading Day, as set forth below, on which the Investor receives a Put
Notice; however, a Put Notice shall be deemed delivered on (a)
the Trading Day it is received by facsimile or otherwise by the Investor if such notice is received prior to 9:00 am Eastern
Time, or (b) the immediately succeeding Trading Day
if it is received by facsimile or otherwise after 9:00 am Eastern Time on a Trading Day.  No Put Notice may be deemed
delivered on a day that is not a Trading Day.

 

“Put
Restriction” shall mean the days between the beginning of the Pricing Period and Closing Date.  During
this time, the Company shall not be entitled to deliver another Put Notice.

 

“Put
Shares Due” shall have the meaning specified in Section 2(I).

 

“Registration
Period” shall have the meaning specified in Section 5(C), below.

 

“Registration
Rights Agreement” shall have the meaning set forth in the recitals, above.

 

“Registration
Statement” means a registration statement of the Company filed under the 1933 Act covering the Securities
issuable hereunder.

 

“Related
Party” shall have the meaning specified in Section 5(H).

 

“Resolution”
shall have the meaning specified in Section 8(E).

 

“SEC”
shall mean the U.S. Securities & Exchange Commission.

 

“Securities”
shall mean the Shares of Common Stock issued pursuant to the terms of the Agreement.

 

“Shares”
shall mean the shares of the Company’s Common Stock.

 

“Subsidiaries”
shall have the meaning specified in Section 4(A).

 

“Term
Sheet” shall mean an executed instrument between the parties hereto containing the terms of this and other
agreements between the parties, and is hereby incorporated by reference. If any conflict exists between the terms or provisions
of the Term Sheet and this Agreement, the latter shall prevail.

 

“Trading
Day” shall mean any day on which the Principal Market for the Common Stock is open for trading, from the
hours of 9:30 am until 4:00 pm.

 

    	4

    	 

    

 

“VWAP”
shall mean the volume weighted average price of the Common Stock during a given period of time.

 

SECTION 2. PURCHASE AND SALE OF COMMON STOCK. 

 

(A) PURCHASE AND SALE OF COMMON STOCK. Subject to the
terms and conditions set forth herein, the Company shall issue and sell to the Investor, and the Investor shall purchase from the
Company, up to that number of Shares having an aggregate Purchase Price of twenty five million dollars ($25,000,000) (the “Facility
Amount”).

 

(B) DELIVERY OF PUT NOTICES. Subject to the terms and
conditions of the Equity Line Transaction Documents, and from time to time during the Open Period, the Company may, in its sole
discretion, deliver a Put Notice to the Investor which states the dollar amount (designated in U.S. Dollars) (the “Put Amount”)
which the Company intends to sell to the Investor on a Closing Date (the “Put”). The Put Notice shall be in the form
attached hereto as Exhibit C and incorporated herein by reference. The amount that the Company shall be entitled to Put to the
Investor (the “Put Amount”) shall be up to twenty five million dollars ($25,000,000). During the Open Period, the Company
shall not be entitled to submit a Put Notice until after the previous Closing has been completed. The Purchase Price for the Common
Stock identified in the Put Notice shall be the Purchase Price.

 

(C) RESERVED

 

(D) RESERVED

 

(E) CONDITIONS TO INVESTOR’S OBLIGATION TO PURCHASE
SHARES. Notwithstanding anything to the contrary in this Agreement, the Company shall not be entitled to deliver a Put Notice
and the Investor shall not be obligated to purchase any Shares at a Closing (as defined in Section 2(G)) unless each of the following
conditions are satisfied:

 

(I) a Registration Statement shall have
been declared effective and shall remain effective and available for the resale of all the Registrable Securities (as defined in
the Registration Rights Agreement) at all times until the Closing with respect to the subject Put Notice;

 

    	5

    	 

    

 

(II) at all times during the period beginning
on the related Put Notice Date and ending on and including the related Closing Date, the Common Stock shall have been listed and/or
eligible for quotation on the Principal Market and shall not have been suspended from trading and/or quotation thereon for a period
of two (2) consecutive Trading Days during the Open Period and the Company shall not have been notified of any pending or threatened
proceeding or other action to suspend the trading and/or quotation of the Common Stock;

 

(III) the Company has complied with its
obligations and is otherwise not in breach of or in default under this Agreement, the Registration Rights Agreement, or any other
agreement executed in connection herewith which has not been cured prior to the Put Notice Date;

 

(IV) no injunction shall have been issued
and remain in force, or action commenced by a governmental authority which has not been stayed or abandoned, prohibiting the purchase
or the issuance of the Securities; and

 

(V) with respect to all Puts, the issuance
of the Securities will not violate any shareholder approval requirements of the Principal Market.

 

If any of the events described in clauses (I) through (V) above
occurs during a Pricing Period, then the Investor shall have no obligation to purchase the Put Amount of Common Stock set forth
in the applicable Put Notice.

 

(F) RESERVED.

 

(G) MECHANICS OF PURCHASE OF SHARES BY INVESTOR. Subject
to the satisfaction of the conditions set forth in Sections 2(E), 7, and 8, the closing of the purchase by the Investor of Securities
pursuant to a Put (a “Closing”) shall occur on the date which is no later than five (5) Trading Days following the
applicable Put Notice Date (each a “Closing Date”). Prior to or on each Closing Date, (I) the Investor shall deliver
to the Company the Purchase Price to be paid for such Securities, and (II) the Company shall deliver to the Investor certificates
representing the Securities to be issued to the Investor on such date and registered in the name of the Investor. In lieu of delivering
physical certificates representing the Securities, and provided that the Company’s transfer agent is then participating in
the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”) program, upon request
of the Investor, the Company shall use commercially reasonable efforts to cause its transfer agent to electronically transmit the
Securities by crediting the account of the Investor’s prime broker (as specified by the Investor within a reasonably in advance
of the Investor’s notice) with DTC through its Deposit Withdrawal Agent Commission (“DWAC”) system.

 

    	6

    	 

    

 

The Company understands that a delay in the issuance of Securities
beyond the Closing Date could result in economic damage to the Investor. After the Effective Date, as compensation to the Investor
for such loss, the Company agrees to make late payments to the Investor for late issuance of Securities (delivery of Securities
after the applicable Closing Date) in accordance with the following schedule (where “No. of Days Late” is defined as
the number of trading days beyond the Closing Date, with the Amounts being cumulative):

 

	LATE PAYMENT FOR EACH
	NO. OF DAYS LATE $10,000 WORTH OF COMMON STOCK
	 	 
	1	$100
	2 	$200
	3 	$300
	4 	$400
	5 	$500
	6 	$600
	7 	$700
	8 	$800
	9 	$900
	10 	$1,000
	Over 10	$1,000 + $200 fo reach
	 	Business Day late beyond 10 days

  

Provided, however, that the Company shall not be liable for,
and shall not be required to make late payment for, any loss that results from a delay in the issuance of Securities caused by
the Investor, the Investor’s broker-dealer and/or prime broker, or DTC.

 

The Company shall make any payments incurred under this Section
in immediately available funds upon demand by the Investor. Nothing herein shall limit the Investor’s right to pursue actual
damages for the Company’s failure to issue and deliver the Securities to the Investor, except that such late payments shall
offset any such actual damages incurred by the Investor, and any Open Market Adjustment Amount, as set forth below.

 

(H) OVERALL LIMIT ON COMMON STOCK
ISSUABLE. Notwithstanding anything contained herein to the contrary, if, during the Open Period, the Company becomes listed
on an exchange that limits the number of shares of Common Stock that may be issued without shareholder approval, then the number
of Shares issuable by the Company and purchasable by the Investor, shall not exceed that number of the shares of Common Stock that
may be issuable without shareholder approval (the “Maximum Common Stock Issuance”).  If such issuance of shares
of Common Stock could cause a delisting on the Principal Market, then the Maximum Common Stock Issuance shall first be approved
by the Company’s shareholders in accordance with applicable law and the By-laws and Certificate of Incorporation of the Company,
as amended. The parties understand and agree that the Company’s failure to seek or obtain such shareholder approval shall
in no way adversely affect the validity and due authorization of the issuance and sale of Securities or the Investor’s obligation
in accordance with the terms and conditions hereof to purchase a number of Shares in the aggregate up to the Maximum Common Stock
Issuance limitation, and that such approval pertains only to the applicability of the Maximum Common Stock Issuance limitation
provided in this Section 2(H).

 

    	7

    	 

    

 

(I)  ADDITIONAL PENALTIES. If, by the third (3rd)
Trading Day after the Closing Date, the Company fails to deliver any portion of the shares of the Put to the Investor (the “Put
Shares Due”) and the Investor purchases, in an open market transaction or otherwise, shares of Common Stock necessary to
make delivery by the Investor of Shares in respect of sales to subsequent purchasers, pursuant to transactions entered into before
the Closing Date (“Subsequent Purchasers”), which such Shares would have been delivered to the Investor by the Company
but for the Company’s failure to so deliver (the “Open Market Share Purchase”), then the Company shall pay to
the Investor, in addition to any other amounts due to Investor pursuant to the Put, and not in lieu thereof, the Open Market Adjustment
Amount (as defined below).  The “Open Market Adjustment Amount” is the amount equal to the excess, if any, of
(x) the Investor’s total purchase price (including brokerage commissions, if any) for the Open Market Share Purchase minus
(y) the net proceeds (after brokerage commissions, if any) received by the Investor from the sale of the Put Shares Due to such
Subsequent Purchasers.  The Company shall pay the Open Market Adjustment Amount to the Investor in immediately available funds
within five (5) Trading Days of written demand by the Investor.  By way of illustration and not in limitation of the foregoing,
if the Investor purchases Shares of Common Stock having a total purchase price (including brokerage commissions, if any) of $11,000
to cover an Open Market Share Purchase with respect to Shares of Common Stock it sold for net proceeds of $10,000, the Open Market
Share Purchase Adjustment Amount which the Company will be required to pay to the Investor will be $1,000, provided the Investor
shall provide written proof of its losses to the Company.

 

(J)  LIMITATION ON AMOUNT OF OWNERSHIP. Notwithstanding
anything to the contrary in this Agreement, in no event shall the Investor be entitled to purchase that number of Shares, which
when added to the sum of the number of shares of Common Stock beneficially owned (as such term is defined under Section 13(d) and
Rule 13d-3 of the 1934 Act), by the Investor, would exceed 9.99% of the number of shares of Common Stock outstanding on the Closing
Date, as determined in accordance with Rule 13d-1(j) of the 1934 Act.

 

    	8

    	 

    

 

SECTION 3. INVESTOR’S REPRESENTATIONS, WARRANTIES,
AND COVENANTS. 

 

The Investor represents and warrants to the Company, and covenants,
as follows:

 

(A) SOPHISTICATED INVESTOR. The Investor has, by reason
of its business and financial experience, such knowledge, sophistication, and experience in financial and business matters and
in making investment decisions of this type that it is capable of (I) evaluating the merits and risks of an investment in the Securities
and making an informed investment decision; (II) protecting its own interest; and (III) bearing the economic risk of such investment
for an indefinite period of time.

 

(B) AUTHORIZATION; ENFORCEMENT. The Investor has the
requisite power and authority to enter into and perform this Agreement. The execution and delivery of this Agreement by the Investor
and the consummation by it of the transactions contemplated hereby and thereby have been duly and validly authorized by the Investor,
and no further consent or authorization is required by its members. This Agreement has been duly and validly authorized, executed,
and delivered on behalf of the Investor and is a valid and binding agreement of the Investor enforceable against the Investor in
accordance with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable
creditors’ rights and remedies.

 

(C) SECTION 9 OF THE 1934 ACT. During the term of this
Agreement, the Investor will comply with the provisions of Section 9 of the 1934 Act, and the rules promulgated thereunder, with
respect to transactions involving the Common Stock. The Investor agrees not to sell the Company’s stock short, either directly
or indirectly through its affiliates, principals or advisors, the Company’s common stock during the term of this Agreement.

 

(D) ACCREDITED INVESTOR. Investor is an “Accredited
Investor” as that term is defined in Rule 501(a) of Regulation D of the 1933 Act and the Dodd-Frank Wall Street Reform and
Consumer Protection Act.

 

(E) NO CONFLICTS. The execution, delivery, and performance
of the Equity Line Transaction Documents by the Investor and the consummation by the Investor of the transactions contemplated
hereby and thereby will not (I) result in a violation of the limited liability company operating agreement or other organizational
documents of the Investor, or (II) conflict with, or constitute a material default (or an event which, with notice or lapse of
time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration, or cancellation
of, any material agreement, contract, indenture mortgage, indebtedness, or instrument to which the Investor is a party, or to the
Investor’s knowledge, result in a violation of any law, rule, regulation, order, judgment, or decree (including federal and
state securities laws and regulations) applicable to the Investor or by which any property or asset of the Investor is bound or
affected.

 

    	9

    	 

    

 

(F) OPPORTUNITY TO DISCUSS. The Investor has received
all materials relating to the Company’s business, finance and operations which it has requested. The Investor has had an
opportunity to discuss the business, management, and financial affairs of the Company and the terms and conditions of this Agreement
and the merits and risks of investing in the Securities with the Company’s management sufficient to enable it to evaluate
its investment. The Investor has had the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

 

(G) INVESTMENT PURPOSES. The Investor is purchasing the
Securities for its own account for investment purposes and not with a view towards distribution and agrees to resell or otherwise
dispose of the Securities solely in accordance with the registration provisions of the 1933 Act (or pursuant to an exemption from
such registration provisions).

 

(H) NO REGISTRATION AS A DEALER. The Investor is not
and will not be required to be registered as a “dealer” under the 1934 Act, either as a result of its execution and
performance of its obligations under this Agreement or otherwise.

 

(I)  GOOD STANDING.  The Investor is a limited
liability company, duly formed, validly existing, and in good standing in the State of Delaware.

 

(J)  TAX LIABILITIES.  The Investor understands
that it is liable for its own tax liabilities.

 

(K) REGULATION M.  The Investor will comply with
Regulation M under the 1934 Act, if applicable.  

 

(L) INVESTOR FUNDS.  The Investor has, and will
have at each Closing, all funds or financing in place necessary to pay and deliver to the Company the cash Purchase Price as contemplated
hereby.

 

    	10

    	 

    

 

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

Except as set forth in the Schedules attached hereto, or as
may be disclosed and amended from time to time on the Company’s reports, schedules, forms, statements and other documents
that may be required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act filed with the SEC and/or
FINRA (the “SEC Documents”) after the Effective Date, the Company represents and warrants to the Investor as follows:

 

(A) ORGANIZATION AND QUALIFICATION. The Company is a
corporation duly organized and validly existing in good standing under the laws of the State of Maryland, and has the requisite
corporate power and authorization to own its properties and to carry on its business as now being conducted. Both the Company and
the companies it owns or controls (“Subsidiaries”) are duly qualified to do business and are in good standing in every
jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary,
except to the extent that the failure to be so qualified or be in good standing would not have a Material Adverse Effect. As used
in this Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets,
operations, results of operations, financial condition or prospects of the Company and its Subsidiaries, if any, taken as a whole,
or on the transactions contemplated hereby or by the agreements and instruments to be entered into in connection herewith, or on
the authority or ability of the Company to perform its obligations under the Equity Line Transaction Documents (as defined in Section
1 and 4(B), below).  

 

(B) AUTHORIZATION; ENFORCEMENT; COMPLIANCE WITH OTHER INSTRUMENTS.

 

(I) The Company has the requisite corporate
power and authority to enter into and perform this Agreement and the Registration Rights Agreement (collectively, the “Equity
Line Transaction Documents”), and at any time during the Agreement after the Effective Date, to issue the Securities in accordance
with the terms hereof and thereof.

 

(II) The execution and delivery of the Equity
Line Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including,
without limitation, the reservation for issuance and the issuance of the Securities pursuant to this Agreement, have been duly
and validly authorized by the Company’s Board of Directors and shareholders, and no further consent or authorization is required
by the Company, its Board of Directors, or its shareholders.

 

(III) The Equity Line Transaction Documents
have been duly and validly executed and delivered by the Company.

 

    	11

    	 

    

 

(IV) The Equity Line Transaction Documents
constitute the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except
as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

(C) CAPITALIZATION.

 

Except as disclosed in Schedule 4(c) and as may be disclosed
in the Company’s SEC Documents or other publicly available filings with the SEC and/or FINRA after the Effective Date:

 

	(I)	No shares of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or
encumbrances suffered or permitted by the Company;

 

	(II)	There are no outstanding debt securities;

 

	(III)	There are no outstanding shares of capital stock, options, warrants, scrip, rights to subscribe to, calls or commitments of
any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any
of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries
is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants,
scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, any shares of capital stock of the Company or any of its Subsidiaries;

 

	(IV)	There are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale
of any of their securities under the 1933 Act (except the Registration Rights Agreement);

 

	(V)	There are no outstanding securities of the Company or any of its Subsidiaries which contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may
become bound to redeem a security of the Company or any of its Subsidiaries;

 

    	12

    	 

    

 

	(VI)	There are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance
of the Securities as described in this Agreement;

 

	(VII)	The Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan
or agreement; and

 

	(VIII)	There is no dispute as to the classification of any shares of the Company’s capital stock.

 

The Company has furnished to the Investor true and correct copies
of the Company’s Certificate of Incorporation, as in effect on the date hereof (the “Certificate of Incorporation”),
and the Company’s By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities convertible
into or exercisable for Common Stock and the material rights of the holders thereof in respect thereto.

 

(D) ISSUANCE OF SHARES. The Company agrees to reserve
adequate Shares for issuance pursuant to this Agreement, which have been duly authorized and reserved those Shares for issuance
(subject to adjustment pursuant to the Company’s covenant set forth in Section 5(F) below) pursuant to this Agreement. Upon
issuance in accordance with this Agreement, the Securities will be validly issued, fully paid for and non-assessable and free from
all taxes, liens and charges with respect to the issue thereof. In the event the Company cannot reserve a sufficient number of
Shares for issuance pursuant to this Agreement, the Company will use its best efforts to authorize and reserve for issuance the
number of Shares required for the Company to perform its obligations hereunder as soon as reasonably practicable.

 

(E) NO CONFLICTS. The execution, delivery, and performance
of the Equity Line Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby
and thereby will not: (I) result in a violation of the Certificate of Incorporation, any Certificate of Designations, Preferences
and Rights of any outstanding series of preferred stock of the Company, or the By-laws; or (II) conflict with, or constitute a
material default (or an event which with notice or lapse of time or both would become a material default) under, or give to others
any rights of termination, amendment, acceleration, or cancellation of, any material agreement, contract, indenture mortgage, indebtedness,
or instrument to which the Company or any of its Subsidiaries is a party, or to the Company’s knowledge result in a violation
of any law, rule, regulation, order, judgment, or decree (including federal and state securities laws and regulations and the rules
and regulations of the Principal Market or principal securities exchange or trading market on which the Common Stock is to be traded
or listed) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its
Subsidiaries is bound or affected. Except as disclosed in Schedule 4(e), neither the Company nor its Subsidiaries is in violation
of any term of, or in default under, the Certificate of Incorporation, any Certificate of Designations, Preferences and Rights
of any outstanding series of preferred stock of the Company or the By-laws or their organizational charter or by-laws, respectively,
or any contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree, or order or any statute, rule, or
regulation applicable to the Company or its Subsidiaries, except for possible conflicts, defaults, terminations, amendments, accelerations,
cancellations, and violations that would not individually or in the aggregate have or constitute a Material Adverse Effect. The
business of the Company and its Subsidiaries is not being conducted, and shall not be conducted, in violation of any law, statute,
ordinance, rule, order, or regulation of any governmental authority or agency, regulatory or self-regulatory agency, or court,
except for possible violations the sanctions for which either individually or in the aggregate would not have a Material Adverse
Effect. Except as specifically contemplated by this Agreement and as required under the 1933 Act, the 1934 Act, or any securities
laws of any states, to the Company’s knowledge, the Company is not required to obtain any consent, authorization, permit
or order of, or make any filing or registration (except the filing of a registration statement as outlined in the Registration
Rights Agreement between the Parties) with, any court, governmental authority or agency, regulatory or self-regulatory agency,
or other third party in order for it to execute, deliver, or perform any of its obligations under, or contemplated by, the Equity
Line Transaction Documents in accordance with the terms hereof or thereof. All consents, authorizations, permits, orders, filings,
and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on
or prior to the date hereof and are in full force and effect as of the date hereof or are pending. Except as disclosed in Schedule
4(e), the Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.
The Company will not be in violation of the listing requirements of the Principal Market as in effect on the date hereof and on
each of the Closing Dates and is not aware of any facts which would reasonably lead to delisting of the Common Stock by the Principal
Market in the foreseeable future.  

 

    	13

    	 

    

 

(F) RESERVED.

 

(G) ABSENCE OF CERTAIN CHANGES. The Company does not
intend to change the business operations of the Company in any material way. The Company has not taken any steps, and does not
currently expect to take any steps, to seek protection pursuant to any bankruptcy law nor does the Company or its Subsidiaries
have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy proceedings.  

 

(H) ABSENCE OF LITIGATION AND/OR REGULATORY PROCEEDINGS.
Except as set forth in Schedule 4(h), there is no action, suit, proceeding, inquiry or investigation before or by any court, public
board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened against or affecting the Company, the Common Stock or any of the Company’s Subsidiaries or any of the Company’s
or the Company’s Subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could
have a Material Adverse Effect.

 

    	14

    	 

    

 

(I) ACKNOWLEDGMENT REGARDING INVESTOR’S PURCHASE OF
SHARES. The Company acknowledges and agrees that the Investor is acting solely in the capacity of an arm’s length purchaser
with respect to the Equity Line Transaction Documents and the transactions contemplated hereby and thereby. The Company further
acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Equity Line Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the
Investor or any of its respective representatives or agents in connection with the Equity Line Transaction Documents and the transactions
contemplated hereby and thereby is merely incidental to the Investor’s purchase of the Securities, and is not being relied
on by the Company. The Company further represents to the Investor that the Company’s decision to enter into the Equity Line
Transaction Documents has been based solely on the independent evaluation by the Company and its representatives.

 

(J) RESERVED.

 

(K)
EMPLOYEE RELATIONS. Neither the Company nor any of its Subsidiaries is involved in any union labor dispute, nor,
to the knowledge of the Company or any of its Subsidiaries, is any such dispute threatened. Neither the Company nor any of its
Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that relations with
their employees are good. No executive officer (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer
intends to leave the Company’s employ or otherwise terminate such officer’s employment with the Company.  

 

(L) INTELLECTUAL PROPERTY RIGHTS. To the Company’s
knowledge, the Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade names, service
marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental
authorizations, trade secrets, and rights necessary to conduct their respective businesses as now conducted. Except as set forth
in Schedule 4(l), to the Company’s knowledge, none of the Company’s trademarks, trade names, service marks, service
mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, government authorizations,
trade secrets, or other intellectual property rights necessary to conduct its business as now or as proposed to be conducted have
expired or terminated, or are expected to expire or terminate within two (2) years from the date of this Agreement. The Company
and its Subsidiaries do not have any knowledge of any infringement by the Company or its Subsidiaries of trademark, trade name
rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, trade
secret, or other similar rights of others, or of any such development of similar or identical trade secrets or technical information
by others and, except as set forth in the Schedule 4(l), there is no claim, action or proceeding being made or brought against,
or to the Company’s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name,
patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or
other infringement; and the Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any
of the foregoing. The Company and its Subsidiaries have taken commercially reasonable security measures to protect the secrecy,
confidentiality, and value of all of their intellectual properties.

 

    	15

    	 

    

 

(M) ENVIRONMENTAL LAWS. The Company and its Subsidiaries
(I) are, to the knowledge of the management and directors of the Company and its Subsidiaries, in compliance with any and all applicable
foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or
hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”); (II) have, to the knowledge
of the management and directors of the Company, received all permits, licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (III) are in compliance, to the knowledge of the  management
and directors of the Company, with all terms and conditions of any such permit, license or approval where, in each of the three
(3) foregoing cases, the failure to so comply would have, individually or in the aggregate, a Material Adverse Effect.

 

(N) TITLE. The Company and its Subsidiaries have good
and marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries,
in each case free and clear of all liens, encumbrances, and defects except such as are described in Schedule 4(n) or such as do
not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property
by the Company or any of its Subsidiaries. Any real property and facilities held under lease by the Company or any of its Subsidiaries
are held by them under valid, subsisting, and enforceable leases with such exceptions as are not material and do not interfere
with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. 

 

(O) INSURANCE. The Company and each of its Subsidiaries,
where applicable, are or will be insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as management of the Company reasonably believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any of its Subsidiaries has been refused any insurance coverage sought
or applied for and neither the Company nor its Subsidiaries has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

 

    	16

    	 

    

 

(P)
 REGULATORY PERMITS. The Company and its Subsidiaries have in full force and effect all certificates, approvals,
authorizations, and permits from the appropriate federal, state, local, or foreign regulatory authorities and comparable foreign
regulatory agencies, necessary to own, lease, or operate their respective properties and assets and conduct their respective businesses,
and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification
of any such certificate, approval, authorization or permit, except for such certificates, approvals, authorizations, or permits
which if not obtained, or such revocations or modifications which, would not have a Material Adverse Effect.

 

(Q)
RESERVED.

 

(R)
 RESERVED.

 

(S) TAX STATUS. Except as set forth on Schedule 4(s),
the Company and each of its Subsidiaries has made or filed all United States federal and state income and all other tax returns,
reports, and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and
each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported
taxes) and has paid all taxes and other governmental assessments and charges that are Material in Amount, shown or determined to
be due on such returns, reports, and declarations, except those being contested in good faith and has set aside on its books provision
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply. Except as set forth on Schedule 4(s), there are no unpaid taxes in any Material Amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company know of no basis for any such claim.

 

(T) CERTAIN TRANSACTIONS. Except as set forth in Schedule
4(t), or filed with the SEC and/or FINRA at least ten (10) days prior to the first Put Notice, but after the Effective Date and
except for arm’s length transactions pursuant to which the Company makes payments in the ordinary course of business upon
terms no less favorable than the Company could obtain from disinterested third parties and other than the grant of stock options
disclosed in Schedule 4(t), none of the officers, directors, or employees of the Company is presently a party to any transaction
with the Company or any of its Subsidiaries (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property
to or from, or otherwise requiring payments to or from any officer, director, or such employee or, to the knowledge of the Company,
any corporation, partnership, trust, or other entity in which any officer, director, or any such employee has a substantial interest
or is an officer, director, trustee, or partner.

 

    	17

    	 

    

 

(U)
DILUTIVE EFFECT. The Company understands and acknowledges that the number of shares of Common Stock issuable upon
purchases pursuant to this Agreement will increase in certain circumstances including, but not necessarily limited to, the circumstance
wherein the trading price of the Common Stock declines during the period between the Effective Date and the end of the Open Period.
The Company’s executive officers and directors have studied and fully understand the nature of the transactions contemplated
by this Agreement and recognize that they have a potential dilutive effect on the shareholders of the Company. The Board of Directors
of the Company has concluded, in its good faith business judgment, and with full understanding of the implications, that such issuance
is in the best interests of the Company. The Company specifically acknowledges that, subject to such limitations as are expressly
set forth in the Equity Line Transaction Documents, its obligation to issue shares of Common Stock upon purchases pursuant to this
Agreement is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests
of other shareholders of the Company.  

 

(V) LOCK-UP. The Company shall cause its officers, insiders,
directors, and affiliates or other related parties under control of the Company, to refrain from buying and/or selling Common Stock
during each Pricing Period.

 

(W) NO GENERAL SOLICITATION. Neither the Company, nor
any of its affiliates, nor any person acting on its behalf, has engaged in any form of general solicitation or general advertising
(within the meaning of Regulation D) in connection with the offer or sale of the Common Stock to be offered as set forth in this
Agreement.

 

(X) 
NO BROKERS, FINDERS OR FINANCIAL ADVISORY FEES OR COMMISSIONS.  No brokers, finders, or financial advisory fees
or commissions will be payable by the Company, its agents or Subsidiaries, with respect to the transactions contemplated by this
Agreement, except as otherwise disclosed in this Agreement.

 

SECTION 5. COVENANTS OF THE COMPANY 

 

(A) 
COMMERCIALLY REASONABLE EFFORTS. The Company shall use all commercially reasonable efforts to timely satisfy each
of the conditions set forth in Section 7 of this Agreement.

 

    	18

    	 

    

 

(B)
BLUE SKY. The Company shall, at its sole cost and expense, on or before each of the Closing Dates, take such action
as the Company shall reasonably determine is necessary to qualify the Securities for, or obtain exemption for the Securities for,
sale to the Investor at each of the Closings pursuant to this Agreement under applicable securities or “Blue Sky” laws
of such states of the United States, as reasonably specified by the Investor in writing at least ten (10) days prior to each of
the Closing Dates, and shall provide evidence of any such action so taken to the Investor on or prior to the Closing Date.

 

(C) REPORTING STATUS. At any time during this Agreement
after the Effective Date, if the Company shall become registered pursuant to Section 12 of the 1934 Act, or if the Company becomes
subject to the 1934 Act reporting requirements pursuant to Section 15(d) of the 1933 Act, the Company shall file all reports required
to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status, or take an action or fail to
take any action, which would terminate its status as a reporting company under the 1934 Act, until one of the following occurs:
(i) this Agreement terminates pursuant to Section 9 and the Investor has the right to sell all of the Securities without restrictions
pursuant to Rule 144(b) promulgated under the 1933 Act or another applicable exemption, or (ii) the date on which the Investor
has sold all the Securities and this Agreement has been terminated pursuant to Section 9.

 

(D) USE OF PROCEEDS. The Company will use the proceeds
from the sale of the Shares (excluding amounts paid by the Company for fees as set forth in the Equity Line Transaction Documents)
for general corporate and working capital purposes and acquisitions or assets, businesses or operations or for other purposes that
the Board of Directors, in its good faith deem to be in the best interest of the Company.  

 

(E) FINANCIAL INFORMATION. During the Open Period, if
the Company shall become registered pursuant to Section 12 of the 1934 Act, or if the Company becomes subject to the 1934 Act reporting
requirements pursuant to Section 15(d) of the 1933 Act, the Company agrees to make available to the Investor via EDGAR or other
electronic means the following documents and information on the forms set forth: (I) within ten (10) Trading Days after the filing
thereof with the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q, any Current Reports on Form
8-K and any Registration Statements or amendments filed pursuant to the 1933 Act; (II) copies of any notices and other information
made available or given to the shareholders of the Company generally, contemporaneously with the making available or giving thereof
to the shareholders; and (III) within ten (10) calendar days of filing or delivery thereof, copies of all documents filed with,
and all correspondence sent to, the Principal Market, any securities exchange or market, or the National Association of Securities
Dealers, Inc., unless such information is material nonpublic information.

 

    	19

    	 

    

 

(F)
RESERVATION OF SHARES. The Company shall take all action necessary to at all times have authorized, and reserved
for the purpose of issuance, a sufficient number of shares of Common Stock to provide for the issuance of the Securities to the
Investor as required hereunder. In the event that the Company determines that it does not have a sufficient number of authorized
shares of Common Stock to reserve and keep available for issuance as described in this Section 5(F), the Company shall use all
commercially reasonable efforts to increase the number of authorized shares of Common Stock by seeking shareholder approval for
the authorization of such additional shares.

 

(G)
LISTING. The Company shall promptly secure or initiate, as described in the definition of Principal Markets from
Section 1, and maintain the listing of all of the Registrable Securities (as defined in the Registration Rights Agreement) on the
Principal Market and each other national securities exchange and automated quotation system, if any, upon which shares of Common
Stock are then listed (subject to official notice of issuance) and shall maintain, such listing of all Registrable Securities from
time to time issuable under the terms of the Equity Line Transaction Documents. Neither the Company nor any of its Subsidiaries
shall take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock on the Principal
Market (excluding suspensions of not more than one (1) Trading Day resulting from business announcements by the Company). The Company
shall promptly provide to the Investor copies of any notices it receives from the Principal Market regarding the continued eligibility
of the Common Stock for listing on such automated quotation system or securities exchange. The Company shall pay all fees and expenses
in connection with satisfying its obligations under this Section 5(G).

 

(H) TRANSACTIONS WITH AFFILIATES. The Company shall not,
and shall cause each of its Subsidiaries not to, enter into, amend, modify, or supplement, or permit any Subsidiary to enter into,
amend, modify, or supplement, any agreement, transaction, commitment, or arrangement with any of its or any Subsidiary’s
officers, directors, persons who were officers or directors at any time during the previous two (2) years, shareholders who beneficially
own 5% or more of the Common Stock, or Affiliates or with any individual related by blood, marriage or adoption to any such individual
or with any entity in which any such entity or individual owns a 5% or more beneficial interest (each a “Related Party”),
except for (I) customary employment arrangements and benefit programs on reasonable terms, (II) any agreement, transaction, commitment,
or arrangement on an arms-length basis on terms no less favorable than terms which would have been obtainable from a disinterested
third party other than such Related Party, or (III) any agreement, transaction, commitment or arrangement which is approved by
a majority of the disinterested directors of the Company. For purposes hereof, any director who is also an officer of the Company
or any Subsidiary of the Company shall not be a disinterested director with respect to any such agreement, transaction, commitment,
or arrangement. “Affiliate” for purposes hereof means, with respect to any person or entity, another person or entity
that, directly or indirectly, (I) has a 5% or more equity interest in that person or entity, (II) has 5% or more common ownership
with that person or entity, (III) controls that person or entity, or (IV) is under common control with that person or entity. “Control”
or “Controls” for purposes hereof means that a person or entity has the power, directly or indirectly, to conduct or
govern the policies of another person or entity.

 

    	20

    	 

    

 

(I) RESERVED.

 

(J) CORPORATE EXISTENCE. The Company shall use all commercially
reasonable efforts to preserve and continue the corporate existence of the Company.

 

(K)
NOTICE OF CERTAIN EVENTS AFFECTING REGISTRATION; SUSPENSION OF RIGHT TO MAKE A PUT. The Company shall promptly notify
the Investor upon the occurrence of any of the following events in respect of a Registration Statement or related prospectus in
respect of an offering of the Securities: (I) receipt of any request for additional information by the SEC or any other federal
or state governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements
to the Registration Statement or related prospectus; (II) the issuance by the SEC or any other federal or state governmental authority
of any stop order suspending the effectiveness of any Registration Statement or the initiation of any proceedings for that purpose;
 (III) receipt of any notification with respect to the suspension of the qualification or exemption from qualification of
any of the Securities for sale in any jurisdiction or the initiation or notice of any proceeding for such purpose; (IV) the happening
of any event that makes any statement made in such Registration Statement or related prospectus or any document incorporated or
deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the
Registration Statement, related prospectus or documents so that, in the case of a Registration Statement, it will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading; and (V) the Company’s reasonable determination that a post-effective
amendment to the Registration Statement would be appropriate, and the Company shall promptly make available to Investor any such
supplement or amendment to the related prospectus. The Company shall not deliver to Investor any Put Notice during the continuation
of any of the foregoing events in this Section 5(K).  

 

(L)   REIMBURSEMENT.  If (I) the Investor becomes
involved in any capacity in any action, proceeding or investigation brought by any shareholder of the Company, in connection with
or as a result of the consummation of the transactions contemplated by the Equity Line Transaction Documents, or if the Investor
is impleaded in any such action, proceeding or investigation by any person (other than as a result of a breach of the Investor’s
representations and warranties set forth in this Agreement); or (II) the Investor becomes involved in any capacity in any action,
proceeding or investigation brought by the SEC against or involving the Company or in connection with or as a result of the consummation
of the transactions contemplated by the Equity Line Transaction Documents (other than as a result of a breach of the Investor’s
representations and warranties set forth in this Agreement), or if this Investor is impleaded in any such action, proceeding or
investigation by any person, then in any such case, the Company will reimburse the Investor for its reasonable legal and other
expenses (including the cost of any investigation and preparation) incurred in connection therewith, as such expenses are incurred.
In addition, other than with respect to any matter in which the Investor is a named party, the Company will pay to the Investor
the charges, as reasonably determined by the Investor, for the time of any officers or employees of the Investor devoted to appearing
and preparing to appear as witnesses, assisting in preparation for hearings, trials or pretrial matters, or otherwise with respect
to inquiries, hearing, trials, and other proceedings relating to the subject matter of this Agreement. The reimbursement obligations
of the Company under this section shall be in addition to any liability which the Company may otherwise have, shall extend upon
the same terms and conditions to any affiliates of the Investor that are actually named in such action, proceeding or investigation,
and partners, directors, agents, employees, attorneys, accountants, auditors and controlling persons (if any), as the case may
be, of Investor and any such affiliate, and shall be binding upon and inure to the benefit of any successors of the Company, the
Investor and any such affiliate and any such person.

 

    	21

    	 

    

 

(M) TRANSFER AGENT.  Upon effectiveness of the Registration
Statement, and for so long as the Registration Statement is effective, the Company shall deliver instructions to its transfer agent
to issue Shares to the Investor that are subject to a Put and are covered for resale by the Registration Statement free of restrictive
legends.

 

(N) ACKNOWLEDGEMENT OF TERMS.  The Company hereby
represents and warrants to the Investor that: (i) it is voluntarily entering into this Agreement of its own freewill, (ii) it is
not entering this Agreement under economic duress, (iii) the terms of this Agreement are reasonable and fair to the Company, and
(iv) the Company has had independent legal counsel of its own choosing review this Agreement, advise the Company with respect to
this Agreement, and represent the Company in connection with this Agreement.

 

SECTION 6. RESERVED

 

SECTION 7. CONDITIONS OF THE COMPANY’S OBLIGATION
TO SELL. 

 

The obligation hereunder of the Company to issue and sell the
Securities to the Investor is further subject to the satisfaction, at or before each Closing Date, of each of the following conditions
set forth below. These conditions are for the Company’s sole benefit and may be waived by the Company at any time in its
sole discretion.

 

    	22

    	 

    

 

(A) The Investor shall have executed this Agreement and the
Registration Rights Agreement and delivered the same to the Company.

 

(B) The Investor shall have delivered to the Company the Purchase
Price for the Securities being purchased by the Investor between the end of the Pricing Period and the Closing Date via a Put Settlement
Sheet (attached hereto as Exhibit D).

 

(C) The representations and warranties of the Investor shall
be true and correct in all material respects as of the date when made and as of the applicable Closing Date as though made at that
time and the Investor shall have performed, satisfied, and complied in all material respects with the covenants, agreements, and
conditions required by the Equity Line Transaction Documents to be performed, satisfied, or complied with by the Investor on or
before such Closing Date.

 

(D) No statute, rule, regulation, executive order, decree, ruling,
or injunction shall have been enacted, entered, promulgated, or endorsed by any court or governmental authority of competent jurisdiction
which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

SECTION 8. FURTHER CONDITIONS OF THE INVESTOR’S
OBLIGATION TO PURCHASE.

 

The obligation of the Investor hereunder to purchase Shares
is subject to the satisfaction, on or before each Closing Date, of each of the following conditions set forth below.

 

(A) The Company shall have executed the Equity Line Transaction
Documents and delivered the same to the Investor.

 

(B) The Common Stock shall be authorized for quotation on the
Principal Market and trading in the Common Stock shall not have been suspended by the Principal Market or the SEC, at any time
beginning on the date hereof and through and including the respective Closing Date (excluding suspensions of not more than one
(1) Trading Day resulting from business announcements by the Company, provided that such suspensions occur prior to the Company’s
delivery of the Put Notice related to such Closing).

 

(C) The representations and warranties of the Company shall
be true and correct as of the date when made and as of the applicable Closing Date as though made at that time and the Company
shall have performed, satisfied and complied with the covenants, agreements, and conditions required by the Equity Line Transaction
Documents to be performed, satisfied or complied with by the Company on or before such Closing Date. The Investor may request an
update as of such Closing Date regarding the representation contained in Section 4(C) above.

 

    	23

    	 

    

 

(D) The Company shall have executed and delivered to the Investor
the certificates representing, or have executed electronic book-entry transfer of, the Securities (in such denominations as the
Investor shall request) being purchased by the Investor at such Closing.

 

(E) The Board of Directors of the Company shall have adopted
resolutions consistent with Section 4(B)(II) above (the “Resolutions”) and such Resolutions shall not have been amended
or rescinded prior to such Closing Date.

 

(F) RESERVED

 

(G) No statute, rule, regulation, executive order, decree, ruling,
or injunction shall have been enacted, entered, promulgated, or endorsed by any court or governmental authority of competent jurisdiction
which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

(H) The Registration Statement shall be effective on each Closing
Date and no stop order suspending the effectiveness of the Registration Statement shall be in effect or, to the Company’s
knowledge, shall be pending or threatened. Furthermore, on each Closing Date (I) neither the Company nor the Investor shall have
received notice that the SEC has issued or intends to issue a stop order with respect to such Registration Statement or that the
SEC otherwise has suspended or withdrawn the effectiveness of such Registration Statement, either temporarily or permanently, or
intends or has threatened to do so (unless the SEC’s concerns have been addressed and Investor is reasonably satisfied that
the SEC no longer is considering or intends to take such action), and (II) no other suspension of the use or withdrawal of the
effectiveness of such Registration Statement or related prospectus shall exist.  

 

(I) At the time of each Closing, the Registration Statement
(including information or documents incorporated by reference therein) and any amendments or supplements thereto shall not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading or which would require public disclosure or an update supplement to the prospectus.

 

(J) If applicable, the shareholders of the Company shall have
approved the issuance of any Shares in excess of the Maximum Common Stock Issuance in accordance with Section 2(H) or the Company
shall have obtained appropriate approval pursuant to the requirements of the State of Maryland and the Company’s Articles
of Incorporation and By-laws.

 

    	24

    	 

    

 

(K) The conditions to such Closing set forth in Section 2(E)
shall have been satisfied on or before such Closing Date.

 

(L)  The Company shall have certified to the Investor the
number of Shares of Common Stock outstanding when a Put Notice is given to the Investor.  The Company’s delivery of
a Put Notice to the Investor constitutes the Company’s certification of the existence of the necessary number of shares of
Common Stock reserved for issuance.

 

SECTION
9. TERMINATION.

 

		A.	This Agreement shall terminate upon any of the following events:

 

(I)when the Investor has purchased
an aggregate of twenty five million dollars ($25,000,000) in the Common Stock of the Company pursuant to this Agreement; or,

 

(II)on the date which is eighteen
(18) months after the Execution Date; or,

 

		(III)	upon written notice of the Company to the Investor.  Any and all shares, or penalties, if any, due under this Agreement
shall be immediately payable and due upon termination of the Line.

 

		B.	This Agreement may terminate upon any of the following events:

 

(I)Termination for Default.
In the event that either party commits a material breach of its obligations hereunder, the other party may, at its option, terminate
this Agreement by written notice of termination specifying such material breach; provided, however, that if such default is subject
to cure, then such notice shall be subject to a twenty (20) day cure period from the date thereof, and if the defaulting party
cures such default prior to expiration of such period, termination shall not take place.

 

(II)Termination for Insolvency.
Either party hereto may, at its option, upon five (5) days written notice, terminate this Agreement should the other party
hereto (i) admit in writing its inability to pay its debts generally as they become due; (ii) make a general assignment
for the benefit of creditors; (iii) institute proceedings to be adjudicated a voluntary bankrupt, or consent to the filing
of a petition of bankruptcy against it; (iv) be adjudicated by a court of competent jurisdiction as being bankrupt or insolvent;
(v) seek reorganization under any bankruptcy act, or consent to the filing of a petition seeking such reorganization, or (vi) have
a decree entered against it by a court of competent jurisdiction appointing a receiver, liquidator, trustee or assignee in bankruptcy
or in insolvency covering all or substantially all of such party’s property or providing for the liquidation of such party’s
property or business affairs.

 

    	25

    	 

    

 

		C.	Survival of Termination. The obligations of the parties under this Agreement that by their nature would continue beyond
expiration, termination or cancellation of this Agreement (including, without limitation, the warranties, indemnification obligations,
confidentiality requirements and ownership and property rights) shall survive any such expiration, termination or cancellation.

 

SECTION 10.  SUSPENSION

 

This Agreement shall be suspended upon any of the following
events, and shall remain suspended until such event is rectified:

 

(I)  the trading of the Common Stock
is suspended by the SEC, the Principal Market or FINRA for a period of two (2) consecutive Trading Days during the Open Period;
or,

 

(II) the Common Stock ceases to be registered
under the 1934 Act or listed or traded on the Principal Market.

 

Immediately upon the occurrence of one of
the above-described events, the Company shall send written notice of such event to the Investor.

 

SECTION
11. INDEMNIFICATION.

 

		(A)	In consideration of the parties mutual obligations set forth in the Transaction Documents, each of the parties (in such capacity,
an “Indemnitor”) shall defend, protect, indemnify, and hold harmless the other and all of the other party’s shareholders,
officers, directors, employees, counsel, and direct or indirect investors and any of the foregoing person’s agents or other
representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement)
(collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs,
penalties, fees, liabilities, and damages, and reasonable expenses in connection therewith (irrespective of whether any such Indemnitee
is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements
(the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (I) any
misrepresentation or breach of any representation or warranty made by the Indemnitor or any other certificate, instrument, or document
contemplated hereby or thereby; (II) any breach of any covenant, agreement, or obligation of the Indemnitor contained in the Equity
Line Transaction Documents or any other certificate, instrument, or document contemplated hereby or thereby; or (III) any cause
of action, suit, or claim brought or made against such Indemnitee by a third party and arising out of or resulting from the execution,
delivery, performance, or enforcement of the Equity Line Transaction Documents or any other certificate, instrument or document
contemplated hereby or thereby, except insofar as any such misrepresentation, breach or any untrue statement, alleged untrue statement,
omission or alleged omission is made in reliance upon and in conformity with information furnished to Indemnitor which is specifically
intended for use in the preparation of any such Registration Statement, preliminary prospectus, prospectus or amendments to the
prospectus. To the extent that the foregoing undertaking by the Indemnitor may be unenforceable for any reason, the Indemnitor
shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible
under applicable law. The indemnity provisions contained herein shall be in addition to any cause of action or similar rights Indemnitor
may have, and any liabilities to which the Indemnitor or the Indemnitees may be subject.

 

    	26

    	 

    

 

		(B)	Promptly after receipt by an Indemnitee under this Section 11 of notice of any action or proceeding (including any governmental
action or proceeding) involving an indemnifiable claim, such Indemnitee shall, if a claim in respect thereof is to be made against
Indemnitor under this Section 11, deliver to Indemnitor a written notice thereof, and Indemnitor shall have the right to participate
in, and, to the extent Indemnitor so desires to assume control of the defense thereof with counsel mutually satisfactory to Indemnitor
and Indemnitee; provided, however, that an Indemnitee, shall have the right to retain its own counsel with the fees and expenses
to be paid by Indemnitor, if, in the reasonable opinion of counsel retained by Indemnitee, the representation by counsel of Indemnitee
and Indemnitor would be inappropriate due to actual or potential differing interests between such Indemnitee and any other party
represented by such counsel in such proceeding. Indemnitor shall pay for only one (1) separate legal counsel for Indemnitee(s),
as applicable selected by it. Indemnitee shall cooperate fully with Indemnitor in connection with any negotiation or defense of
any such action or claim by Indemnitor and shall furnish to Indemnitor all information reasonably available to Indemnitee which
relates to such action or claim. Indemnitor shall keep Indemnitee fully apprised at all times as to the status of the defense or
any settlement negotiations with respect thereto. Indemnitor shall not be liable for any settlement of any action, claim or proceeding
affected without its written consent; provided, however, that Indemnitor shall not unreasonably withhold, delay or condition its
consent. No indemnifying party shall, without the consent of Indemnitee, consent to entry of any judgment or enter into any settlement
or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnitee
of a release from all liability in respect to such claim. Following indemnification as provided for hereunder, Indemnitor shall
be subrogated to all rights of Indemnitee with respect to all third parties, firms or corporations relating to the matter for which
indemnification has been made. The failure to deliver written notice to Indemnitor within a reasonable time of the commencement
of any such action shall not relieve Indemnitor of any liability to Indemnitee under this Section 11, except to the extent
that Indemnitor is prejudiced in its ability to defend such action.

 

    	27

    	 

    

 

SECTION
12. GOVERNING LAW.

 

(A) GOVERNING LAW. All disputes arising under this agreement
shall be governed by and interpreted in accordance with the laws of New York, without regard to principles of conflict of laws.
  

 

(B) LEGAL FEES AND MISCELLANEOUS FEES. Except as otherwise
set forth in the Equity Line Transaction Documents, each party shall pay the fees and expenses of its advisers, counsel, the accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery,
and performance of this Agreement. Any attorneys’ fees and expenses incurred by either the Company or the Investor relating
to the enforcement of the rights of any party, after the occurrence of any breach of the terms of this Agreement by another party
or any default by another party in respect of the transactions contemplated hereunder, shall be paid on demand by the party which
breached the Agreement and/or defaulted, as the case may be. The Company shall pay all stamp and other taxes and duties levied
in connection with the issuance of any Securities.

 

(C) COUNTERPARTS. This Agreement may be executed in two
or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party; provided, however, that a .PDF signature shall be considered due
execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.

 

(D) HEADINGS; SINGULAR/PLURAL. The headings of this Agreement
are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. Whenever required
by the context of this Agreement, the singular shall include the plural and masculine shall include the feminine.

 

(E) SEVERABILITY. If any provision of this Agreement
shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability
of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in
any other jurisdiction.

 

    	28

    	 

    

 

(F) ENTIRE AGREEMENT; AMENDMENTS. This Agreement is the
final agreement between the Company and the Investor with respect to the terms and conditions set forth herein, and, the terms
of this Agreement may not be contradicted by evidence of prior, contemporaneous, or subsequent oral agreements of the Parties.
 No provision of this Agreement may be amended other than by an instrument in writing signed by the Company and the Investor,
and no provision hereof may be waived other than by an instrument in writing signed by the party against whom enforcement is sought.
The execution and delivery of the Equity Line Transaction Documents shall not alter the force and effect of any other agreements
between the Parties, and the obligations under those agreements. 

 

(G) NOTICES. Any notices or other communications required
or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered (I) upon
receipt, when delivered personally; (II) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically
or electronically generated and kept on file by the sending party); or (III) one (1) day after deposit with a nationally recognized
overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be:

 

If to the Company:

 

Vaccinogen, Inc.

5300 Westview Drive, Suite 406

Frederick, MD 21703

Fax: (301) 631-2970

 

with a copy to:

 

Indeglia & Carney

1900 Main Street, Suite 300

Irvine, CA 92614

marc@indegliacarney.com

Fax: (949) 861-3324

 

If to the Investor:

 

Kodiak Capital Group, LLC

260 Newport Center Drive, Suite 100

Newport Beach, CA 92660

ryan@kodiak-capital.com

 

    	29

    	 

    

 

Each party shall provide five (5) days prior written notice
to the other party of any change in address, facsimile number, or e-mail address.

 

(H) NO ASSIGNMENT. This Agreement may not be assigned.

 

(I) NO THIRD PARTY BENEFICIARIES. This Agreement is intended
for the benefit of the parties hereto and is not for the benefit of, nor may any provision hereof be enforced by, any other person,
except that the Company acknowledges that the rights of the Investor may be enforced by its general partner.

 

(J) SURVIVAL. The representations and warranties of the
Company and the Investor contained in Sections 2 and 3, the agreements and covenants set forth in Sections 4 and 5, and the indemnification
provisions set forth in Section 11, shall survive each of the Closings and the termination of this Agreement.  

 

(K) PUBLICITY. The Company
and the Investor shall consult with each other in issuing any press releases or otherwise making public statements with respect
to the transactions contemplated hereby and no party shall issue any such press release or otherwise make any such public statement
without the prior consent of the other party, which consent shall not be unreasonably withheld or delayed, except that no prior
consent shall be required if such disclosure is required by law, in which such case the disclosing party shall provide the other
party with prior notice of such public statement. Notwithstanding the foregoing, the Company shall not publicly disclose the name
of the Investor without the prior consent of the Investor, except to the extent required by law. The Investor acknowledges that
this Agreement and all or part of the Equity Line Transaction Documents may be deemed to be “material contracts” as
that term is defined by Item 601(b)(10) of Regulation S-K, and that the Company may therefore be required to file such documents
as exhibits to reports or registration statements filed under the 1933 Act or the 1934 Act.  The Investor further agrees that
the status of such documents and materials as material contracts shall be determined solely by the Company, in consultation with
its counsel.

 

(L) FURTHER ASSURANCES. Each party shall do and perform,
or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates,
instruments, and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes
of this Agreement and the consummation of the transactions contemplated hereby.

 

(M) COMMITMENT FEES; OTHER FEES RELATED TO THE TRANSACTION.
In addition to the Shares to be issued pursuant to the Facility Amount, the Company agrees to issue additional shares as follows:

 

    	30

    	 

    

 

		(I)	the Company shall be solely responsible for all commissions, fees and / or transaction costs associated and / or related to,
in any way, with the transaction and / or transactions herein contemplated and or agreed to under this Agreement.

		(II)	the Company shall pay to the Investor the balance of the Document Preparation Fee of $25,000 on the Execution Date for the
preparation of the Agreement.

		(III)	the Company shall issue to the Investor 236,364 Shares of Common Stock (the “Commitment Shares”) on the Execution
Date, pursuant to Section 4(2) of the 1933 Act.

 

(N) NO STRICT CONSTRUCTION. The language used in this
Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction
will be applied against any party, as the parties mutually agree that each has had a full and fair opportunity to review this Agreement
and seek the advice of counsel on it. The normal rule that ambiguities shall be interpreted against the drafting party shall not
apply in the instant case.

 

(O) REMEDIES. The Investor shall have all rights and
remedies set forth in this Agreement and the Registration Rights Agreement and all rights and remedies which such holders have
been granted at any time under any other agreement or contract and all of the rights which the Investor has by law. Any person
having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting
a bond or other security), to recover damages by reason of any default or breach of any provision of this Agreement, including
the recovery of reasonable attorney’s fees and costs, and to exercise all other rights granted by law.

 

(P) PAYMENT SET ASIDE. To the extent that the Company
makes a payment or payments to the Investor hereunder or under the Registration Rights Agreement or the Investor enforces or exercises
its rights hereunder or thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof
are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any
such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

(Q) PRICING OF COMMON STOCK. For purposes of this Agreement,
the lowest daily VWAP of the Common Stock shall be as reported on Bloomberg.

 

    	31

    	 

    

 

SECTION 13. NON-DISCLOSURE OF NON-PUBLIC INFORMATION.

 

(A) Once the Company has secured, initiated, and maintained
the listing or quotation of the Shares on the Principal Market and each other national securities exchange and automated quotation
system, the Company shall not disclose non-public information to the Investor, its advisors, or its representatives.

 

(B) Nothing herein shall require the Company, once it has secured,
initiated, and maintained the listing of the Shares on the Principal Market and each other national securities exchange and automated
quotation system, to disclose non-public information to the Investor or its advisors or representatives, and the Company represents
that it does not disseminate non-public information to any investors who purchase stock in the Company in a public offering, to
money managers or to securities analysts, provided, however, that notwithstanding anything herein to the contrary, the Company
will, as hereinabove provided, immediately notify the advisors and representatives of the Investor and, if any, underwriters, of
any event or the existence of any circumstance (without any obligation to disclose the specific event or circumstance) of which
it becomes aware, constituting non-public information (whether or not requested of the Company specifically or generally during
the course of due diligence by such persons or entities), which, if not disclosed in the prospectus included in the Registration
Statement would cause such prospectus to include a material misstatement or to omit a material fact required to be stated therein
in order to make the statements, therein, in light of the circumstances in which they were made, not misleading. Nothing contained
in this Section 13 shall be construed to mean that such persons or entities other than the Investor (without the written consent
of the Investor prior to disclosure of such information) may not obtain non-public information in the course of conducting due
diligence in accordance with the terms of this Agreement and nothing herein shall prevent any such persons or entities from notifying
the Company of their opinion that based on such due diligence by such persons or entities, that the Registration Statement contains
an untrue statement of material fact or omits a material fact required to be stated in the Registration Statement or necessary
to make the statements contained therein, in light of the circumstances in which they were made, not misleading.  

 

[Remainder of page intentionally left
blank.]

 

    	32

    	 

    

 

SIGNATURE PAGE OF INVESTMENT AGREEMENT 

 

Your signature on this Signature Page evidences your agreement
to be bound by the terms and conditions of the Investment Agreement and the Registration Rights Agreement as of the date first
written above.

 

The undersigned signatory hereby certifies that he has read
and understands the Investment Agreement, and the representations made by the undersigned in this Investment Agreement are true
and accurate, and agrees to be bound by its terms.

 

	KODIAK CAPITAL GROUP,
    LLC	 
	 	 
	By:   	/s/ Ryan C. Hodson	 
	 	Ryan C. Hodson	 
	 	Managing Director	 
	 	 
	VACCINOGEN, INC.	 
	 	 
	By:	 /s/ Andrew L. Tussing	 
	 	Andrew L. Tussing	 
	 	President & Chief Operating Officer	 
	 	 
	By:	 /s/ Michael G. Hanna, Jr., Ph.D.	 
	 	Michael G. Hanna, Jr., Ph.D.	 
	 	Chairman & Interim Chief Executive Officer	 

 

    	33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]